상세 정보

underline
Metadata Downloads : dc(xml) or Excel
Cited 0 time in scopus ci

Title 

Enhanced anticancer effects of a methylation inhibitor by inhibiting a novel DNMT1 target, CEP 131, in cervical cancer

Authors 

Dong Hyun KimHye-Min KimP T T HuongHo Jin HanJoonsung HwangHyunjoo ChaKyung Ho LeeIn Ja RyooK E KimY H HuhJong Seog AhnY T KwonNak Kyun SoungBo Yeon Kim

Publisher 

Korean Society for Biochemistry and Molecular Biology

Issue Date 

2019

Citation 

BMB Reports

Keywords 

Anti-cancerCentrosomeCEP131DNMT1

Abstract 

Methylation is a primary epigenetic mechanism regulating gene expression. 5-aza-2’-deoxycytidine is an FDA-approved drug prescribed for treatment of cancer by inhibiting DNA-Methyl-Transferase 1 (DNMT1). Results of this study suggest that prolonged treatment with 5-aza-2’-deoxycytidine could induce centrosome abnormalities in cancer cells and that CEP131, a centrosome protein, is regulated by DNMT1. Interestingly, cancer cell growth was attenuated in vitro and in vivo by inhibiting the expression of Cep131. Finally, Cep131-deficient cells were more sensitive to treatment with DNMT1 inhibitors. These findings suggest that Cep131 is a potential novel anti-cancer target. Agents that can inhibit this protein may be useful alone or in combination with DNMT1 inhibitors to treat cancer.

URI 

https://doi.org/10.5483/BMBRep.2019.52.5.055

ISSN 

1225-8687

Appears in Collections

1. Journal Articles > Journal Articles

Registered Date

2019-07-10


There are no files associated with this item.
qrcode

FusionCharts.
DSpace Software Coptright(c) 2010 MIT and Hewleft-Packard  /  KRIBB-REPOSITORY ( Email:jakim@kribb.re.kr)